A PRAGMATIC ADAPTIVE RANDOMIZED, CONTROLLED PHASE II/III MULTICENTER STUDY OF IFX-1 IN PATIENTS WITH SEVERE COVID-19 PNEUMONIA

To demonstrate the efficacy of IFX-1 to improve survival outcomes of severe COVID-19 pneumonia (confirmative)

Study-ID: 2020-001335-28

DZL Disease Area: PALI

Study Type: Interventional

DZL Role: DZL recruiting center

Funding: Externally - industry

DZL Participating Sites: BREATH

Start Date: 04.02.2021

Completion Date: 01.06.2022

Status: Closed

Disease: Severe pneumonia in context of Coronavirus Disease-19 (COVID-19)

EUCT/CTIS Number: 2020-001335-28